{{Rsnum
|rsid=4460176
|Chromosome=5
|position=110161259
|Orientation=plus
|GMAF=0.4954
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 46.0 | 42.5 | 11.5
| HCB | 14.2 | 40.3 | 45.5
| JPT | 7.1 | 42.0 | 50.9
| YRI | 7.5 | 45.2 | 47.3
| ASW | 21.1 | 49.1 | 29.8
| CHB | 14.2 | 40.3 | 45.5
| CHD | 11.1 | 48.1 | 40.7
| GIH | 26.0 | 58.0 | 16.0
| LWK | 12.7 | 46.4 | 40.9
| MEX | 19.0 | 48.3 | 32.8
| MKK | 12.9 | 54.8 | 32.3
| TSI | 54.9 | 41.2 | 3.9
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs4460176
|PubMedID=17903294
|Condition=Hemostatic factors and hematological phenotypes
|Gene=Intergenic
|Risk Allele=
|pValue=3.00E-006
|OR=NA
|95CI=
|OA=1
}}

{{PharmGKB
|RSID=rs4460176
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17903294; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study (Initial Sample Size: 1,000 individuals (Framingham; Replication Sample Size: NR). This variant is associated with Hemostatic factors and hematological phenotypes.
|Drugs=
|Drug Classes=
|Diseases=Hematologic Diseases
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356461
}}

{{PMID Auto
|PMID=17903299
|Title=A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study.
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4460176
|overall_frequency_n=64
|overall_frequency_d=126
|overall_frequency=0.507936
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=51
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}